Cabot (CBT) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.78 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 2.15%. A quarter ago, it was expected that this chemical company would post earnings of $1.80 per share when it actually produced earnings of $1.76, delivering a surprise of -2.22%. Over the last four quarters, the company ...

Core Viewpoint - Artivion (AORT) reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share, representing a 50% earnings surprise [1] - The company posted revenues of $98.98 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.19% [2] Financial Performance - Artivion's earnings of $0.06 per share are unchanged from the same quarter last year, and the company has surpassed consensus EPS estimates two times over the last four quarters [1][2] - The company has topped consensus revenue estimates three times in the last four quarters, with year-ago revenues of $97.43 million [2] Stock Performance - Artivion shares have declined approximately 18.4% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current Zacks Rank for Artivion is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $108.7 million, and for the current fiscal year, it is $0.68 on revenues of $426.65 million [7] - The outlook for the Medical - Instruments industry is positive, ranking in the top 28% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Sterling Infrastructure (STRL) reported quarterly earnings of $1.63 per share, exceeding the Zacks Consensus Estimate of $1.58 per share, and showing an increase from $1 per share a year ago, indicating a positive earnings surprise of 3.16% [1] Financial Performance - The company achieved revenues of $430.95 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.69%, although this represents a decline from year-ago revenues of $440.36 million [2] - Over the last four quarters, Sterling Infrastructure has consistently surpassed consensus EPS estimates, achieving this four times [2] Stock Performance - Since the beginning of the year, Sterling Infrastructure shares have decreased by approximately 1.7%, while the S&P 500 has declined by 3.3%, indicating relative outperformance [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.14 on revenues of $535.3 million, and for the current fiscal year, it is $8.21 on revenues of $2.03 billion [7] Industry Context - The Engineering - R and D Services industry, to which Sterling Infrastructure belongs, is currently ranked in the top 15% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Viewpoint - Vertex Pharmaceuticals reported quarterly earnings of $4.06 per share, missing the Zacks Consensus Estimate of $4.22 per share, and showing a decline from $4.76 per share a year ago, indicating an earnings surprise of -3.79% [1] - The company posted revenues of $2.77 billion for the quarter, missing the Zacks Consensus Estimate by 1.72%, but showing an increase from $2.69 billion year-over-year [2] Financial Performance - Over the last four quarters, Vertex has surpassed consensus EPS estimates only once, and has topped consensus revenue estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $4.25 on revenues of $2.89 billion, and for the current fiscal year, it is $17.69 on revenues of $11.86 billion [7] Market Performance - Vertex shares have increased by approximately 24.5% since the beginning of the year, contrasting with a -3.3% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Syndax Pharmaceuticals reported a quarterly loss of $0.98 per share, which was better than the Zacks Consensus Estimate of a loss of $1.04, indicating an earnings surprise of 5.77% [1] Financial Performance - The company posted revenues of $20.04 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 36.69%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.99 on revenues of $17.81 million, and for the current fiscal year, it is -$3.99 on revenues of $81.74 million [7] Stock Performance - Syndax shares have increased by approximately 3.9% since the beginning of the year, while the S&P 500 has declined by 3.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Syndax belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - TG Therapeutics reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share, compared to a loss of $0.07 per share a year ago, representing an earnings surprise of -83.33% [1] - The company posted revenues of $120.86 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.99%, and showing a significant increase from year-ago revenues of $63.47 million [2] - Over the last four quarters, TG Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - TG Therapeutics shares have increased approximately 44.3% since the beginning of the year, while the S&P 500 has declined by -3.3% [3] - The current consensus EPS estimate for the coming quarter is $0.22 on revenues of $131.03 million, and for the current fiscal year, it is $0.98 on revenues of $545.6 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TG Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.64%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.36 per share when it actually produced a loss of $0.53, delivering a surprise of -47.22%.Over the last four quarters ...

Core Viewpoint - Ares Management reported quarterly earnings of $1.09 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.80 per share a year ago, indicating a 15.96% earnings surprise [1] Group 1: Earnings Performance - The company surpassed consensus EPS estimates three times over the last four quarters [2] - Ares Management's revenues for the quarter ended March 2025 were $897.58 million, missing the Zacks Consensus Estimate by 1.76%, compared to $736.42 million in the same quarter last year [2] - The company has topped consensus revenue estimates only once in the last four quarters [2] Group 2: Stock Performance and Outlook - Ares Management shares have declined approximately 11.3% since the beginning of the year, while the S&P 500 has decreased by 3.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.19 on revenues of $1.15 billion, and for the current fiscal year, it is $4.93 on revenues of $4.79 billion [7] Group 3: Industry Context - The Financial - Investment Management industry, to which Ares Management belongs, is currently ranked in the bottom 13% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ares Management's stock performance [5]

Group 1 - TDS reported a quarterly loss of $0.09 per share, missing the Zacks Consensus Estimate of a loss of $0.02, and compared to earnings of $0.10 per share a year ago, representing an earnings surprise of -350% [1] - The company posted revenues of $1.15 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.24%, and down from $1.26 billion year-over-year [2] - TDS shares have increased by approximately 10.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $1.18 billion, and for the current fiscal year, it is -$0.35 on revenues of $4.76 billion [7] - The Zacks Industry Rank for Wireline - National is in the top 38% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Financial Performance - Butterfly Network, Inc. reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.07 per share a year ago, indicating an earnings surprise of 33.33% [1] - The company posted revenues of $21.23 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.58%, but showing an increase from year-ago revenues of $17.66 million [2] - Over the last four quarters, Butterfly Network has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Butterfly Network shares have declined approximately 25% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The company's current Zacks Rank is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $24.46 million, and for the current fiscal year, it is -$0.32 on revenues of $97.54 million [7] - The trend of estimate revisions for Butterfly Network is currently favorable, which could influence future stock movements [5][6] Industry Context - The Medical Info Systems industry, to which Butterfly Network belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]